The Translation Accelerator Kidney Award Scheme (TAKA) will provide funding and support to accelerate the translation of scientific discoveries into new, effective solutions to help understand, prevent, protect, and treat kidney disease, in line with our strategic priorities. This is an expression of interest process.
Our translation awards fund short, discrete, patient and clinic focussed projects to address a specific challenge/question about an innovation that may help it get to the clinic faster. This translational funding can help develop the opportunity and therefore reduce the risk for potential commercial partners. This makes the opportunity more attractive and makes a successful outcome more likely.
We are seeking applications across two parallel workstreams:
- Therapeutics: An intervention intended to prevent, treat, cure, or modify the course of kidney disease through a direct biological, pharmacological, or physiological effect.
- MedTech: Technologies, devices or tools intended to be used for the diagnosis, monitoring, prevention of, or delivery of care for, kidney disease, and which do not achieve their primary intended action by pharmacological, immunological or metabolic means.
Awards are made across two funding levels for a maximum duration of 15 months:
- Level 1 awards will provide up to £79,999
- Level 2 awards will provide between £80,000 and £125,000
We welcome applications from researchers in UK-based higher education institutions, NHS clinicians and clinical researchers, and allied healthcare professionals. Collaborative approaches and team approaches are encouraged.
